Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 23;25(18):10184.
doi: 10.3390/ijms251810184.

The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia

Dominika Sojakova  1   2 , Jitka Husakova  1   2 , Vladimira Fejfarova  1 , Andrea Nemcova  1 , Radka Jarosikova  1 , Simon Kopp  1 , Veronika Lovasova  3   4 , Edward B Jude  5   6 , Michal Dubsky  1   2
Affiliations
Review

The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia

Dominika Sojakova et al. Int J Mol Sci. .

Abstract

Autologous cell therapy (ACT) is primarily used in diabetic patients with chronic limb-threatening ischemia (CLTI) who are not candidates for standard revascularization. According to current research, this therapy has been shown in some studies to be effective in improving ischemia parameters, decreasing the major amputation rate, and in foot ulcer healing. This review critically evaluates the efficacy of ACT in patients with no-option CLTI, discusses the use of mononuclear and mesenchymal stem cells, and compares the route of delivery of ACT. In addition to ACT, we also describe the use of new revascularization strategies, e.g., nanodiscs, microbeads, and epigenetics, that could enhance the therapeutic effect. The main aim is to summarize new findings on subcellular and molecular levels with the clinical aspects of ACT.

Keywords: chronic limb-threatening ischemia; peripheral artery disease; stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Types of stem cells used in ACT are divided into a group of commonly used cells, cell subpopulations, and experimentally used cells.
Figure 2
Figure 2
Cell therapy process using mononuclear stem cells (MNCs) and mesenchymal stem cells (MSCs).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stoberock K., Kaschwich M., Nicolay S.S., Mahmoud N., Heidemann F., Riess H.C., Debus E.S., Behrendt C.A. The interrelationship between diabetes mellitus and peripheral arterial disease. Vasa. 2021;50:323–330. doi: 10.1024/0301-1526/a000925. - DOI - PubMed
    1. Fitridge R., Chuter V., Mills J., Hinchliffe R., Azuma N., Behrendt C.A., Boyko E.J., Conte M.S., Humphries M., Kirksey L., et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. J. Vasc. Surg. 2023;78:1101–1131. doi: 10.1016/j.jvs.2023.07.020. - DOI - PubMed
    1. Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat. Rev. Cardiol. 2022;19:456–474. doi: 10.1038/s41569-021-00663-9. - DOI - PubMed
    1. Jude E.B., Oyibo S.O., Chalmers N., Boulton A.J. Peripheral arterial disease in diabetic and nondiabetic patients: A comparison of severity and outcome. Diabetes Care. 2001;24:1433–1437. doi: 10.2337/diacare.24.8.1433. - DOI - PubMed
    1. Farber A., Menard M.T., Conte M.S., Kaufman J.A., Powell R.J., Choudhry N.K., Hamza T.H., Assmann S.F., Creager M.A., Cziraky M.J., et al. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N. Engl. J. Med. 2022;387:2305–2316. doi: 10.1056/NEJMoa2207899. - DOI - PubMed

MeSH terms

LinkOut - more resources